Quantum Technology - The report highlights the clear positioning of the NISQ (Noisy Intermediate-Scale Quantum) era, indicating that current quantum devices are operational but limited in capability, lacking fault tolerance and scalability. Experts estimate that small-scale fault-tolerant quantum computers will take about ten years to develop [8][9] - The collaboration between Argonne National Laboratory and Intel has successfully deployed a 12-qubit silicon-based quantum processor, demonstrating the value of mature silicon technology in scaling quantum computing [10] - D-Wave has showcased a scalable on-chip low-temperature control gate model quantum bit, significantly reducing wiring costs and addressing a major bottleneck in the industry [12][14] Biomanufacturing - Micro Yuan Synthesis has secured nearly 300 million yuan in financing to accelerate the development of methanol biomanufacturing, which addresses the reliance on food-based raw materials in traditional biomanufacturing [15][16] - The first gene-consistent human "lung chip" has been developed, providing a new tool for personalized treatment of respiratory diseases and potentially revolutionizing drug development by reducing reliance on animal models [18] Hydrogen Energy and Nuclear Fusion - Policies in Shanghai and other regions are reducing the operational costs of hydrogen vehicles through subsidies and free highway access, which is expected to significantly boost the adoption of hydrogen fuel cell vehicles [19][20] - The report notes that hydrogen energy is transitioning from being a major electricity consumer to a "regulator" of the grid, enhancing the consumption of renewable energy and long-term storage capabilities [25][28] - The Energy Singularity's "Honghuang 70" nuclear fusion device has achieved a 120-second steady-state operation, marking a significant milestone in commercial nuclear fusion technology [31] - Dongsheng Fusion has completed a multi-hundred million yuan angel round of financing to develop a "deuterium-helium-3" fusion route, which is considered safer and more cost-effective than traditional methods [32][33] Brain-Computer Interface - Strong Brain Technology has raised 2 billion yuan to scale brain-computer interface technology, aiming to help one million disabled individuals regain social functionality within five to ten years [38][39] - Sichuan Province has set maximum prices for brain-computer interface medical services, which will take effect in April 2026, facilitating the clinical application of this technology [40][41] - The first brain-computer interface deep brain stimulator surgery in Southwest China has been successfully performed, providing new treatment options for Parkinson's disease [42][43] Embodied Intelligence - NVIDIA has released several physical AI models and frameworks that support robots in understanding physical laws, enhancing the industrialization of robots across various scenarios [5][13] - Chinese companies represent nearly 25% of robot exhibitors at CES 2026, with humanoid robots making up over 50% of the exhibition area, showcasing the competitive edge of Chinese firms in this sector [5][13] Sixth Generation Mobile Communication (6G) - Nanjing has launched a special plan to build a 6G industrial ecosystem, aiming for full coverage of 6G non-cellular networks by 2027 and the establishment of over 50 vertical industry scenarios [5][14]

Core Viewpoint - The introduction of the "brain-machine interface" deep brain stimulator represents a significant advancement in the treatment of Parkinson's disease, allowing patients to manage symptoms more effectively and improve their quality of life [1][2]. Group 1: Treatment Overview - Parkinson's disease is a degenerative neurological condition primarily affecting the elderly, with approximately 5 million patients in China, the highest number globally [1]. - Traditional treatment methods include medication, deep brain stimulation surgery, and rehabilitation, with deep brain stimulation recognized as the preferred surgical option [1]. - The newly developed "brain-machine interface" deep brain stimulator is rechargeable and capable of sensing, marking a technological leap in treatment [1][2]. Group 2: Technological Advancements - The new deep brain stimulator incorporates a small computer that reads and analyzes brain signals related to the disease, allowing for dynamic parameter adjustments without the need for frequent hospital visits [2]. - This technology enables a closed-loop treatment system, enhancing patient comfort and reducing the need for manual parameter adjustments that were previously required at set intervals [2]. Group 3: Patient Experiences - Patients like Mr. Xiao, who suffered from Parkinson's for over 15 years, report significant improvements in their symptoms and overall quality of life following the surgery [2]. - Mr. Wang, another patient, expressed gratitude for the advanced technology, highlighting the positive impact on his condition and emotional well-being [2].

Core Viewpoint - The prevalence of Parkinson's disease is increasing, closely linked to population aging and the rise of neurodegenerative diseases like Alzheimer's and Parkinson's [1][3]. Group 1: Understanding Parkinson's Disease - The understanding of Parkinson's disease has evolved significantly over the past 31 years, particularly with the introduction of PET imaging agents that allow for the visualization of dopamine transporters in the brain [3][4]. - The core issue in Parkinson's disease is the loss of dopamine neurons, which leads to symptoms such as tremors, slowness, and stiffness [3][15]. - Tremors are commonly associated with Parkinson's disease, but not all patients exhibit this symptom; slowness is considered the most critical feature for diagnosis [6][8]. Group 2: Diagnosis and Symptoms - Objective tests, particularly PET imaging, are emphasized for accurate diagnosis, as Parkinson's disease symptoms can be subtle and difficult to assess [4][5]. - Key symptoms include slowness, stiffness, and tremors, with slowness being a necessary condition for diagnosis [7][8]. - Distinguishing between age-related slowness and slowness due to Parkinson's is crucial, as they present differently [10][13]. Group 3: Treatment Options - Standard treatment primarily involves medication, particularly dopamine precursors like levodopa, which can improve symptoms significantly [18][19]. - Long-term use of medication may lead to diminished effectiveness, but it is essential for maintaining quality of life [20][22]. - Surgical options, such as Deep Brain Stimulation (DBS), are available for patients who do not respond adequately to medication [23][24]. Group 4: Research and Future Directions - Research is ongoing into the role of alpha-synuclein protein aggregation in Parkinson's disease, with new imaging agents being developed to monitor this process [15][17]. - There is potential for stem cell therapy, but it remains in the clinical trial phase and requires careful evaluation [27][28]. - Preventive measures include lifestyle changes such as exercise and dietary adjustments, which may help reduce the risk of developing Parkinson's disease [32].

Core Insights - Neuromodulation technology shows significant advantages in treating neurological diseases such as epilepsy and Parkinson's disease, enhancing treatment effectiveness and improving patients' quality of life [1][8] - The Chinese neuromodulation industry is projected to reach a market size of approximately 2.285 billion yuan in 2024, reflecting a year-on-year growth of 8.65%, driven by technological innovation and market demand [1][8] Industry Overview - Neuromodulation is a treatment method that regulates nervous system activity through electrical, magnetic, chemical, or other forms of stimulation, aiming to alleviate symptoms and improve functionality [2] - The industry can be categorized into invasive and non-invasive techniques, each comprising various specific technologies [2] Industry Development History - The Chinese neuromodulation industry has evolved over seventy years, starting from foundational research in the 1950s to the current stage of mature expansion, with significant milestones in technology introduction and innovation [2][3] - Key developments include the first DBS surgery in 1998 and the establishment of the first domestic DBS product registration in 2013, marking a shift from technology importation to independent innovation [2][3] Market Size - The neuromodulation market is expected to grow to approximately 2.285 billion yuan in 2024, with an 8.65% increase from the previous year, indicating a dual driving effect of technology transformation and market demand [1][8] Key Companies - Beijing Pincai Medical holds over 25% of the domestic market share with its comprehensive range of neuromodulation products, including DBS and SCS [9][10] - Suzhou Jingyu Medical is a leading player in the DBS field, having received FDA breakthrough device designation for its dual-target DBS technology [10][11] Industry Development Trends 1. Continuous integration of technological innovations will drive precision and intelligent upgrades in the neuromodulation sector, with advancements in AI and brain-computer interfaces expected to enhance treatment efficacy [12] 2. Application scenarios are expanding from traditional disease treatment to cognitive enhancement and emotional regulation, with consumer-grade neuromodulation devices anticipated to see explosive growth [13][14] 3. Policy and industry collaboration will promote domestic production and global expansion, with ongoing government support for brain science initiatives and the inclusion of neuromodulation procedures in insurance reimbursement [15]